48,591 Shares in Surmodics, Inc. (NASDAQ:SRDX) Bought by Olympiad Research LP

Olympiad Research LP purchased a new stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 48,591 shares of the company's stock, valued at approximately $1,884,000. Surmodics comprises about 1.2% of Olympiad Research LP's holdings, making the stock its 15th largest holding. Olympiad Research LP owned 0.34% of Surmodics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in SRDX. Vanguard Group Inc. grew its stake in Surmodics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 865,214 shares of the company's stock valued at $25,385,000 after buying an additional 5,927 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Surmodics by 5.0% in the second quarter. Renaissance Technologies LLC now owns 606,538 shares of the company's stock worth $25,499,000 after acquiring an additional 28,990 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Surmodics by 11.3% in the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company's stock worth $11,988,000 after acquiring an additional 41,617 shares during the period. Gabelli Funds LLC raised its stake in shares of Surmodics by 393.7% during the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company's stock valued at $10,939,000 after purchasing an additional 207,500 shares during the period. Finally, Gardner Lewis Asset Management L P bought a new stake in shares of Surmodics during the 2nd quarter valued at $8,531,000. Institutional investors own 96.63% of the company's stock.

Surmodics Price Performance

Shares of SRDX traded down $0.09 during trading hours on Thursday, reaching $38.40. 160,938 shares of the company's stock traded hands, compared to its average volume of 230,832. Surmodics, Inc. has a 12 month low of $25.17 and a 12 month high of $42.44. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. The stock has a market cap of $547.85 million, a PE ratio of -384.90 and a beta of 1.20. The firm's 50 day simple moving average is $38.62 and its 200-day simple moving average is $38.60.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on SRDX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Thursday. StockNews.com started coverage on shares of Surmodics in a research note on Thursday. They issued a "hold" rating on the stock. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $50.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).